EUVIMEDEUVIMED entdecken
Crossref

Discovery of Novel Autotaxin Inhibitors Bearing the 4,5,6,7‐Tetrahydro‐7 H ‐Pyrazolo[3,4‐ c ]Pyridine‐7‐One Core for Pulmonary Fibrosis Therapy

Jiahe Zhang, Jiachen Zhang, Jiandong Li, Deyi Ma iD, Zehui Tan, Xin Zhai iD

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Jiahe Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, People's Republic o…. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases, Pulmonary Fibrosis, Drug Discovery, Pyrazoles. Die Arbeit nennt 21 Literaturangaben. Gefördert von: This study was supported by China Postdoctoral Science Foundation under Grant Number (2024M762164)..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary fibrosis (PF) is a progressive and fatal disease, and recent studies have revealed its key role in the autotaxin (ATX)‐lysophosphatidic acid (LPA) signaling pathway, revealing the therapeutic potential of targeting ATX. Herein, starting from PAT‐409, a series of novel ATX inhibitors containing the 4,5,6,7‐tetrahydro‐7 H ‐pyrazolo[3,4‐ c ]pyridin‐7‐one core were designed to improve the pharmacological activity and physicochemical properties. The most promising compound 19 exhibited potent ATX inhibition (IC 50 = 4.2 nM) and significantly reduced lipophilicity (cLogP = 2.992) compared with PAT‐409 (IC 50 = 4.9 nM, cLogP = 7.647). Molecular dynamics simulations indicated that 19 bound to the ATX protein in a highly stable manner. Furthermore, predictive analyses of drug‐like properties and toxicity uncovered that 19 demonstrated comparable safety to PAT‐409 while exhibiting significantly superior drug‐like characteristics. This study provides a promising ATX inhibitor for PF therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoric Diester HydrolasesPulmonary FibrosisDrug DiscoveryPyrazolesPyridinesPyridonesPhosphodiesterase InhibitorsStructure-Activity RelationshipHumansMolecular StructureMolecular Dynamics SimulationAnimalsDose-Response Relationship, DrugMolecular Docking SimulationLysophospholipase D

Stichwörter der Autor:innen

4,5,6,7‐tetrahydro‐7H‐pyrazolo[3,4‐c]pyridine‐7‐oneADMET analysisautotaxinpulmonary fibrosis

Substanzen

Phosphoric Diester HydrolasesPyrazolesPyridinesPyridonesPhosphodiesterase InhibitorsLysophospholipase D

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, People's Republic of China.

ORCID-Profile: Deyi Ma, Xin Zhai

Förderung

  • This study was supported by China Postdoctoral Science Foundation under Grant Number (2024M762164).

Zitieren

APA

Zhang, J., Zhang, J., Li, J., Ma, D., Tan, Z., & Zhai, X. (2025). Discovery of Novel Autotaxin Inhibitors Bearing the 4,5,6,7‐Tetrahydro‐7 H ‐Pyrazolo[3,4‐ c ]Pyridine‐7‐One Core for Pulmonary Fibrosis Therapy. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70095

Vancouver

Zhang J, Zhang J, Li J, Ma D, Tan Z, Zhai X. Discovery of Novel Autotaxin Inhibitors Bearing the 4,5,6,7‐Tetrahydro‐7 H ‐Pyrazolo[3,4‐ c ]Pyridine‐7‐One Core for Pulmonary Fibrosis Therapy. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70095

BibTeX
@article{Zhang2025,
  author = {Zhang, Jiahe and Zhang, Jiachen and Li, Jiandong and Ma, Deyi and Tan, Zehui and Zhai, Xin},
  title = {Discovery of Novel Autotaxin Inhibitors Bearing the 4,5,6,7‐Tetrahydro‐7 H ‐Pyrazolo[3,4‐ c ]Pyridine‐7‐One Core for Pulmonary Fibrosis Therapy},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70095}
}
Kostenlos starten →